{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:59:50Z","timestamp":1780667990928,"version":"3.54.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["RIA2017MC-2009"],"award-info":[{"award-number":["RIA2017MC-2009"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ijid.2025.108118","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T04:48:52Z","timestamp":1760071732000},"page":"108118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Increased risk of neuropsychiatric adverse events with dolutegravir-based antiretroviral therapy during pregnancy: Findings from a prospective cohort study"],"prefix":"10.1016","volume":"161","author":[{"given":"Hadijja","family":"Namwase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackson K.","family":"Mukonzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collins","family":"Ankunda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Vella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birkneh Tilahun","family":"Tadesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9788-0790","authenticated-orcid":false,"given":"Eleni","family":"Aklillu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2025.108118_sbref0001","series-title":"Guidelines approved by the guidelines review committee, guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV","year":"2015"},{"key":"10.1016\/j.ijid.2025.108118_bib0002","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s10461-011-9947-5","article-title":"Quality of life among individuals with HIV starting antiretroviral therapy in diverse resource-limited areas of the world","volume":"16","author":"Safren","year":"2012","journal-title":"AIDS Behav"},{"key":"10.1016\/j.ijid.2025.108118_sbref0003","series-title":"HIV and adolescent girls and young women","year":"2024"},{"key":"10.1016\/j.ijid.2025.108118_bib0004","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1097\/QAD.0000000000001845","article-title":"The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?","volume":"32","author":"Vitoria","year":"2018","journal-title":"Aids"},{"key":"10.1016\/j.ijid.2025.108118_bib0005","series-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach","year":"2016"},{"key":"10.1016\/j.ijid.2025.108118_bib0006","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAD.0000000000003070","article-title":"Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy\u2014naive adults with HIV-1 infection","volume":"36","author":"Cahn","year":"2022","journal-title":"Aids"},{"key":"10.1016\/j.ijid.2025.108118_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0000826","article-title":"HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: A systematic review and meta-analysis","volume":"2","author":"Ngoufack Jagni Semengue","year":"2022","journal-title":"PLOS Glob Public Health"},{"key":"10.1016\/j.ijid.2025.108118_bib0008","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/hiv.13373","article-title":"Efficacy, durability, and tolerability of dolutegravir\/lamivudine and dolutegravir\/rilpivirine for the treatment of HIV in a real-world setting in Belgium","volume":"24","author":"Nasreddine","year":"2023","journal-title":"HIV Med"},{"key":"10.1016\/j.ijid.2025.108118_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104552","article-title":"Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected na\u00efve patients: results from a multicenter cohort study","volume":"169","author":"Rossetti","year":"2019","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ijid.2025.108118_bib0010","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12879-021-05850-0","article-title":"Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-na\u00efve patients infected with HIV-1: an update on a systematic review and network meta-analysis","volume":"21","author":"Nickel","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2025.108118_bib0011","doi-asserted-by":"crossref","first-page":"4","DOI":"10.24875\/AIDSRev.19000023","article-title":"Neuropsychiatric adverse events with Dolutegravir and other integrase strand transfer inhibitors","volume":"21","author":"Hoffmann","year":"2019","journal-title":"AIDS Rev"},{"key":"10.1016\/j.ijid.2025.108118_bib0012","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2025.108118_bib0013","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000016721","article-title":"Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-na\u00efve and -experienced patients","volume":"98","author":"Brehm","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ijid.2025.108118_bib0014","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/hiv.13428","article-title":"Prevalence of neuropsychiatric adverse events and associated factors among adult patients on dolutegravir attending Mulago ISS clinic","volume":"24","author":"Mwebaza","year":"2023","journal-title":"HIV Med"},{"key":"10.1016\/j.ijid.2025.108118_bib0015","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/14787210.2023.2203914","article-title":"Real-world discontinuations due to neuropsychiatric symptoms in people living with HIV treated with second-generation integrase inhibitors: a systematic review","volume":"21","author":"P\u00e9rez-Valero","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijid.2025.108118_bib0016","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/03007995.2023.2189855","article-title":"Neuropsychiatric adverse drug reactions and associated factors in a cohort of individuals starting dolutegravir-based or efavirenz-based antiretroviral therapy in Belo Horizonte, Brazil","volume":"39","author":"Mendes","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ijid.2025.108118_bib0017","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/hiv.12468","article-title":"Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients","volume":"18","author":"Hoffmann","year":"2017","journal-title":"HIV Med"},{"key":"10.1016\/j.ijid.2025.108118_bib0018","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/ejhpharm-2020-002374","article-title":"Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study","volume":"29","author":"Fern\u00e1ndez-Bargiela","year":"2022","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.ijid.2025.108118_bib0019","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3389\/fphar.2014.00065","article-title":"Physiologic and pharmacokinetic changes in pregnancy","volume":"5","author":"Costantine","year":"2014","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijid.2025.108118_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.579448","article-title":"Neuropsychiatric adverse events during 12 months of treatment with Efavirenz in treatment-na\u00efve HIV-infected patients in China: a prospective cohort study","volume":"12","author":"Hua","year":"2021","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.ijid.2025.108118_bib0021","series-title":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach","year":"2021"},{"key":"10.1016\/j.ijid.2025.108118_bib0022","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/1471-2334-13-261","article-title":"Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study","volume":"13","author":"Mukonzo","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2025.108118_bib0023","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\"Mini-mental state\". A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.ijid.2025.108118_bib0024","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/jama.282.18.1737","article-title":"Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study","volume":"282","author":"Spitzer","year":"1999","journal-title":"Jama"},{"key":"10.1016\/j.ijid.2025.108118_bib0025","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.genhosppsych.2010.03.006","article-title":"The patient health questionnaire somatic, anxiety, and depressive symptom scales: a systematic review","volume":"32","author":"Kroenke","year":"2010","journal-title":"General hospital psychiatry"},{"key":"10.1016\/j.ijid.2025.108118_bib0026","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2025.108118_bib0027","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1177\/0956462416688127","article-title":"Early clinical experience of dolutegravir in an HIV cohort in a larger teaching hospital","volume":"28","author":"Todd","year":"2017","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.ijid.2025.108118_bib0028","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s12888-025-06820-5","article-title":"Patients reported neuropsychiatric adverse events and associated factors among PLHIV patients receiving DTG-based regimen antiretroviral therapy real-life clinical practice in Ethiopia: multi center crossetional study","volume":"25","author":"Chanie","year":"2025","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.ijid.2025.108118_bib0029","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1590\/S1808-86942010000100006","article-title":"Hearing and vestibular complaints during pregnancy","volume":"76","author":"Schmidt","year":"2010","journal-title":"Braz J Otorhinolaryngol"},{"key":"10.1016\/j.ijid.2025.108118_bib0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5694\/mja17.00131","article-title":"Cognitive impairment during pregnancy: a meta-analysis","volume":"208","author":"Davies","year":"2018","journal-title":"Med J Aust"},{"issue":"Suppl 1","key":"10.1016\/j.ijid.2025.108118_bib0031","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/j.psyneuen.2009.06.013","article-title":"Plasticity and function of extrasynaptic GABA(A) receptors during pregnancy and after delivery","volume":"34","author":"Mostallino","year":"2009","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.ijid.2025.108118_bib0032","article-title":"Steroid hormone sensitivity in reproductive mood disorders: on the role of the GABA(A) receptor complex and stress during hormonal transitions","volume":"7","author":"Schweizer-Schubert","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ijid.2025.108118_bib0033","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1124\/dmd.112.050245","article-title":"Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes?","volume":"41","author":"Isoherranen","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ijid.2025.108118_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2013.09.005","article-title":"Allopregnanolone: state of the art","volume":"113","author":"Melcangi","year":"2014","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.ijid.2025.108118_bib0035","doi-asserted-by":"crossref","first-page":"ofz174","DOI":"10.1093\/ofid\/ofz174","article-title":"Dolutegravir cerebrospinal fluid diffusion in HIV-1-infected patients with Central nervous system impairment","volume":"6","author":"Gel\u00e9","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2025.108118_bib0036","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/cid\/ciu477","article-title":"ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects","volume":"59","author":"Letendre","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2025.108118_bib0037","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1007\/s12035-018-1273-8","article-title":"Nanoformulated antiretroviral therapy attenuates brain metabolic oxidative stress","volume":"56","author":"Montenegro-Burke","year":"2019","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.ijid.2025.108118_bib0038","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3018(15)00027-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study","volume":"2","author":"Molina","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijid.2025.108118_bib0039","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1097\/QAD.0b013e3283612419","article-title":"Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study","volume":"27","author":"Stellbrink","year":"2013","journal-title":"Aids"},{"key":"10.1016\/j.ijid.2025.108118_bib0040","series-title":"Neurological disorders and pregnancy","first-page":"13","article-title":"Headache in pregnancy","author":"Elliott","year":"2011"},{"key":"10.1016\/j.ijid.2025.108118_bib0041","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0238052","article-title":"Dolutegravir: virologic response and tolerability of initial antiretroviral regimens for adults living with HIV","volume":"15","author":"Correa","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2025.108118_bib0042","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222229","article-title":"Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: a systematic review and meta-analysis","volume":"14","author":"Cruciani","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2025.108118_bib0043","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2190\/PLGX-N48F-RBHJ-UF8K","article-title":"Development of acute psychotic disorders and HIV-1 infection","volume":"30","author":"de Ronchi","year":"2000","journal-title":"Int J Psychiatry Med"},{"key":"10.1016\/j.ijid.2025.108118_bib0044","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1017\/S2045796020000906","article-title":"Employment is a critical mental health intervention","volume":"29","author":"Drake","year":"2020","journal-title":"Epidemiol Psychiatr Sci"},{"key":"10.1016\/j.ijid.2025.108118_bib0045","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1093\/cid\/ciae001","article-title":"Weight changes and adverse pregnancy outcomes with Dolutegravir- and Tenofovir alafenamide fumarate-containing antiretroviral treatment regimens during pregnancy and postpartum","volume":"78","author":"Hoffman","year":"2024","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225003406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225003406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:59:57Z","timestamp":1780664397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971225003406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":45,"alternative-id":["S1201971225003406"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108118","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased risk of neuropsychiatric adverse events with dolutegravir-based antiretroviral therapy during pregnancy: Findings from a prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108118","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108118"}}